By Karin McCay| email
Edited by Kristin Beerman | email
LUBBOCK, TX (KCBD) – In a rare move more than a dozen pharmaceutical companies have agreed to share the secrets they've learned from studying Alzheimer's disease. The new database will include information from studies that failed, as well as the successes from the National Institutes of Health and various universities. The goal is to learn what went wrong, and what needs to change in order to speed up development of a drug that can really help these patients.
"I think it's that exciting we have companies, instead of doing their own work on their own and not necessarily learning from each other, are now voluntarily coming together to learn from each other in the interests of moving the whole field forward and finding better treatments for patients," said Joshua Sharfstein, the FDA Deputy Commissioner.
The project is partially funded by the Food and Drug Administration. The hope is that this will be the first of many data-bases shared by drug companies, with Parkinson's and Tuberculosis among the next they are targeting.
©2010 KCBD NewsChannel 11. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.